Table 2 Safety indicators of remdesivir treatment for patients with an eGFR of less than 30 mL/min/1.73m2
Unmatched cohort | Propensity score-matched cohort | |||||
|---|---|---|---|---|---|---|
Remdesivir (N = 229) | Standard care (N = 335) | P value | Remdesivir (N = 178) | Standard care (N = 178) | P value | |
Day 5 laboratory result, median (IQR) | ||||||
Creatinine (mg/dL) | 2.7 (1.7–7.5) | 3.2 (1.9–7.6) | 0.084 | 2.9 (1.7–7.7) | 3 (1.9–6.7) | 0.328 |
AST (IU/L) | 27 (18–40) | 22 (16–32) | 0.003 | 27 (18–39) | 23 (16–33) | 0.037 |
ALT (IU/L) | 19.5 (13–31.25) | 16 (11–24) | 0.001 | 19 (13–29.3) | 15 (10.8–26) | 0.017 |
eGFR (mL/min/1.73m2) | 21.4 (6.85–37) | 16 (6–31) | 0.032 | 20.7 (6.1–37.1) | 18 (7–31) | 0.275 |
New dialysis in those not receiving dialysis at baseline | 14 (6.1) | 6 (1.8) | 0.009 | 14 (7.9) | 5 (2.8) | 0.034 |